Communiqué from annual general meeting in ChromoGenics AB (publ)

The annual general meeting in ChromoGenics AB (publ) was held on 15 May 2019 at Advokatfirman Lindahl’s offices on Vaksalagatan 10 in Uppsala whereby the shareholders resolved on the following main matters.

Annual report and profit and loss statement

The annual general meeting adopted the presented profit and loss statement and the balance sheet and resolved, in accordance with the board of directors’ proposal, to carry the accumulated loss forward in new account. No dividends will be paid for the financial year 2018.

Discharge from liability

The board of directors and the managing director were discharged from liability by the annual general meeting for the financial year 2018.

Remuneration to the board and the auditor

It was resolved that remuneration shall be paid with SEK 125,000 for ordinary board members, and with SEK 250,000 for the chairman. It was resolved that the auditor shall receive remuneration on an open account basis.

Election of board of directors and auditor

Anders Brännström, Claes-Göran Granqvist, Mari Broman and Peter Gustafson were re-elected as directors. Johan Hedin and Peter Edelsvärd were elected as new directors. The general meeting elected Grant Thornton as auditor of the company.

Resolution on adoption of a nomination committee

The annual general meeting resolved that the company, in advance of the general meeting to be held in 2020, shall establish a nomination committee that shall have the task to prepare proposals on, inter alia, members of the board of directors, remuneration and auditor. It was hereby resolved that the members of the nomination committee in advance of the general meeting to be held in 2020 shall be appointed as follows. The chairman shall instruct the three shareholders with the largest holdings of shares/votes in the company to each appoint a representative that together with the chairman shall constitute the nomination committee.

Authorisation to the board of directors to issue new shares, warrants and/or convertible instruments

The annual general meeting resolved to authorise the board of directors to, for the time until the next annual general meeting, at one or several occasions, issue new shares, warrants and/or convertible instruments. The board of directors shall be authorised to adopt decisions on one or several issues of new shares, warrants and/or convertible instruments with or without deviation from the shareholders’ pre-emption rights and/or decide on an issue in kind or an issue by way of set-off of claims or any other conditions in accordance with the provisions of the Swedish Company’s Act. The authorisation can be used to issue not more than 17,275,598 shares and/or warrants, which corresponds to approximately 10 percent of the current number of shares in the Company.

The resolutions from the annual general meeting were adopted unanimously.

Uppsala 15 May 2019

ChromoGenics AB (publ)

The board of directors


Jerker Lundgren, CEO
Tel: +46 (0)18 430 0430
Certified Adviser: G&W Fondkommission

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish version shall prevail.

About ChromoGenics
ChromoGenics offers dynamic glass with controllable heat- and light transmission. The company’s unique technology ConverLight® provides sustainable solar control for increased indoor comfort and energy efficiency. ConverLight® also contributes to Green Building certifications. In 2016 the company started commercial sales to real estate projects in Scandinavia.

ChromoGenics is located in Uppsala, Sweden, and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser. 

Download as PDF


Subscribe to our news